These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16645006)

  • 21. Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.
    Acton JJ; Akiyama TE; Chang CH; Colwell L; Debenham S; Doebber T; Einstein M; Liu K; McCann ME; Moller DE; Muise ES; Tan Y; Thompson JR; Wong KK; Wu M; Xu L; Meinke PT; Berger JP; Wood HB
    J Med Chem; 2009 Jul; 52(13):3846-54. PubMed ID: 19507861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
    Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
    Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients.
    Hansen L; Ekstrøm CT; Tabanera Y Palacios R; Anant M; Wassermann K; Reinhardt RR
    J Clin Endocrinol Metab; 2006 Sep; 91(9):3446-50. PubMed ID: 16822823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
    Liu HJ; Zhang CY; Song F; Xiao T; Meng J; Zhang Q; Liang CL; Li S; Wang J; Zhang B; Liu YR; Sun T; Zhou HG
    J Pharmacol Exp Ther; 2015 Jun; 353(3):573-81. PubMed ID: 25876909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin therapy in renal disease.
    Iglesias P; Díez JJ
    Diabetes Obes Metab; 2008 Sep; 10(10):811-23. PubMed ID: 18248491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peroxisome proliferator-activated receptor (PPAR α/γ) agonists as a potential target to reduce cardiovascular risk in diabetes.
    Nicholls SJ; Uno K
    Diab Vasc Dis Res; 2012 Apr; 9(2):89-94. PubMed ID: 22407927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.
    Karsdal MA; Henriksen K; Genovese F; Leeming DJ; Nielsen MJ; Riis BJ; Christiansen C; Byrjalsen I; Schuppan D
    Diabetologia; 2017 Jan; 60(1):50-59. PubMed ID: 27631136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Examining the safety of PPAR agonists - current trends and future prospects.
    Bortolini M; Wright MB; Bopst M; Balas B
    Expert Opin Drug Saf; 2013 Jan; 12(1):65-79. PubMed ID: 23134541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
    Karak M; Bal NC; Bal C; Sharon A
    Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sulfonylthiadiazoles with an unusual binding mode as partial dual peroxisome proliferator-activated receptor (PPAR) γ/δ agonists with high potency and in vivo efficacy.
    Keil S; Matter H; Schönafinger K; Glien M; Mathieu M; Marquette JP; Michot N; Haag-Diergarten S; Urmann M; Wendler W
    ChemMedChem; 2011 Apr; 6(4):633-53. PubMed ID: 21400663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the treatment of type 2 diabetes mellitus.
    Israili ZH
    Am J Ther; 2011; 18(2):117-52. PubMed ID: 19834322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
    Cavender MA; Lincoff AM
    Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non-diabetic renal diseases.
    Chung BH; Lim SW; Ahn KO; Sugawara A; Ito S; Choi BS; Kim YS; Bang BK; Yang CW
    Nephrology (Carlton); 2005 Oct; 10 Suppl():S40-3. PubMed ID: 16174287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.